-
Johnson & Johnson's $10 Billion Test: 2026 Outlook Could Make Or Break JNJ Heading Into Q4
Tuesday, January 20, 2026 - 5:11am | 606Read More...Pharmaceutical company Johnson & Johnson (NYSE:JNJ) is set to report its fourth-quarter results on Wednesday, facing one of the most important transitions in its modern history, as investors focus on whether the company can replace revenue from its former immunology powerhouse, Stelara. J&J...
-
Johnson & Johnson's CFO On COVID-19 Trial Pause: 'We Are Letting The Science Dictate'
Tuesday, October 13, 2020 - 1:57pm | 419Read More...COVID-19 vaccine developer Johnson & Johnson (NYSE: JNJ) paused an ongoing trial Monday due to an unexplained illness, although it's unknown if the individual in question was given the vaccine or a placebo, J&J CFO Joseph Wolk said on CNBC's "Squawk Box." What...
-
Johnson & Johnson Names Joseph Wolk As VP Of Investor Relations In Place Of Louise Mehrotra
Wednesday, June 22, 2016 - 7:24am | 250Read More...Johnson & Johnson (NYSE: JNJ) revealed Tuesday that Louise Mehrotra, VP of Investor Relations, would retire in January next year, after a transition period with her successor. According to the company, Joseph Wolk would replace the position with effect from August and would report to the CFO...
